Either I’ve got a contact high or the NY Post just let out some interesting information.
High times, indeed. According to a NY Post article that was posted late last night, Origo Acquisition Corporation’s target, High Times, began a Reg A+ funding round this week, exactly one week after shareholders approved the new completion extension date of September 12th. According to High Times, they hope to raise $20 million via the Reg A+ round.
The article quotes High Times’ Chairman, Adam Levin as saying, “It’s a new path to an IPO,” said Levin. “We raised just over $1 million on Day One from 400 people.” He said High Times Holdings priced at $11 a share.”
Admittedly, I do not have any experience with Reg A+ vehicles, but this raises all sorts of questions. This was not in the proxy statement, but it’s also unclear to me if it needed to be. However, I would think this would be material information.
Secondly, Origo’s cash in trust is currently $15 million. If High Times is raising capital via a Reg A+ vehicle to the tune of $20 million, does this mean the merger is off, or is this a concurrent raise? Can you even do a concurrent raise without completely delaying the merger even further?
Having said that, if High Times already has 400 investors in the Reg A+ deal, that would certainly help solve one of the issues of Origo keeping a Nasdaq listing – needing 450 round lot shareholders. This is assuming the merger is still on because the article’s title is “High Times Plots New Path to IPO”. Emphasis on “New Path,“ so it kind of sounds like it’s off?
If anyone has any experience with Reg A+ funding and can help sort this out, please either leave a comment below this article or email me directly.
You can read the article here.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...